BACKGROUND: We conducted a phase II study to determine the response to, and toxicity of, docetaxel (Taxotere; Rhône Poulenc Rorer Pharmaceuticals, Inc) in patients with recurrent malignant glioma. PATIENTS AND METHODS: Eighteen patients with recurrent malignant glioma were treated with 100 mg/m2 (no prior chemotherapy) or 75 mg/m2 (prior adjuvant chemotherapy) of docetaxel intravenously over 1 hour, every 3 weeks. Premedication with dexamethasone, diphenhydramine and ranitidine or cimetidine was given to all patients. Five (28%) had gioblastoma multiforme (GBM) and the rest other malignant gliomas. Eleven (61%) had an ECOG performance status of 0 or 1, and 13 (72%) were on corticosteroids at the start of treatment. Rigorous response criteria were used. All were eligible and evaluable for response. RESULTS: No complete or partial responses were observed; the objective response rate was 0% (95% confidence interval: 0-15.3%). Patients received a median of 2 cycles (range, 1-6). Grade 3 or 4 neutropenia occurred in 17 (94%) patients and was associated with fever that required intravenous antibiotics in 4 (22%) patients. An additional patient received intravenous antibiotics for an infection not associated with neutropenia. Six (33%) patients had mild hypersensitivity reactions. Onychodystrophy, peripheral edema and peripheral neuropathy were uncommon and mild. CONCLUSIONS: Docetaxel has no significant activity in patients with recurrent malignant glioma.
BACKGROUND: We conducted a phase II study to determine the response to, and toxicity of, docetaxel (Taxotere; Rhône Poulenc Rorer Pharmaceuticals, Inc) in patients with recurrent malignant glioma. PATIENTS AND METHODS: Eighteen patients with recurrent malignant glioma were treated with 100 mg/m2 (no prior chemotherapy) or 75 mg/m2 (prior adjuvant chemotherapy) of docetaxel intravenously over 1 hour, every 3 weeks. Premedication with dexamethasone, diphenhydramine and ranitidine or cimetidine was given to all patients. Five (28%) had gioblastoma multiforme (GBM) and the rest other malignant gliomas. Eleven (61%) had an ECOG performance status of 0 or 1, and 13 (72%) were on corticosteroids at the start of treatment. Rigorous response criteria were used. All were eligible and evaluable for response. RESULTS: No complete or partial responses were observed; the objective response rate was 0% (95% confidence interval: 0-15.3%). Patients received a median of 2 cycles (range, 1-6). Grade 3 or 4 neutropenia occurred in 17 (94%) patients and was associated with fever that required intravenous antibiotics in 4 (22%) patients. An additional patient received intravenous antibiotics for an infection not associated with neutropenia. Six (33%) patients had mild hypersensitivity reactions. Onychodystrophy, peripheral edema and peripheral neuropathy were uncommon and mild. CONCLUSIONS:Docetaxel has no significant activity in patients with recurrent malignant glioma.
Authors: J J Heimans; J B Vermorken; J G Wolbers; C M Eeltink; O W Meijer; M J Taphoorn; J H Beijnen Journal: Ann Oncol Date: 1994-12 Impact factor: 32.976
Authors: G Cairncross; D Macdonald; S Ludwin; D Lee; T Cascino; J Buckner; D Fulton; E Dropcho; D Stewart; C Schold Journal: J Clin Oncol Date: 1994-10 Impact factor: 44.544
Authors: M J Glantz; H Choy; C M Kearns; B F Cole; P Mills; E G Zuhowski; S Saris; C H Rhodes; E Stopa; M J Egorin Journal: J Clin Oncol Date: 1996-02 Impact factor: 44.544
Authors: Prakash Sampath; Laurence D Rhines; Francesco DiMeco; Betty M Tyler; Michael C Park; Henry Brem Journal: J Neurooncol Date: 2006-04-25 Impact factor: 4.130
Authors: Padma Kadiyala; Dan Li; Fernando M Nuñez; David Altshuler; Robert Doherty; Rui Kuai; Minzhi Yu; Neha Kamran; Marta Edwards; James J Moon; Pedro R Lowenstein; Maria G Castro; Anna Schwendeman Journal: ACS Nano Date: 2019-02-11 Impact factor: 15.881
Authors: Asbiel Hasbum; Jaqueline Quintanilla; Juan A Amieva Jr; May-Hui Ding; Arkene Levy; Sue Anne Chew Journal: Future Med Chem Date: 2021-01-05 Impact factor: 3.808